Ontogeny of Gut Dendritic Cells in Steady State and Inflamed Settings

稳态和炎症环境下肠道树突状细胞的个体发育

基本信息

  • 批准号:
    7766964
  • 负责人:
  • 金额:
    $ 42.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-02-01 至 2012-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Dendritic cells (DCs) are highly specialized antigen presenting cells found in all lymphoid and non-lymphoid tissues. In the traditional view, DCs are terminally differentiated cells constantly replaced by a pool of circulating precursors. In contrast to this view, we recently demonstrated that in mice, epidermal DCs also called Langerhans cells (LCs) are maintained by local radio-resistant proliferative precursors, throughout life in quiescent skin, and are replaced by circulating precursors only during injuries. We have also discovered that host radio-resistant LCs can persist in recipient mice after allogeneic bone marrow transplant (allo-BMT). Graft versus host disease (GVHD) is a major cause of mortality and morbidity after allo-BMT. Importantly, we found that persistence of host LCs after allo-BMT correlates with severe skin GVHD, while replacement of host LCs by donor LCs improves skin GVHD outcome. Therefore, exploring DC homeostasis in a tissue target of GVHD may help develop new strategies for the treatment of this devastating disease. In addition to LCs, we recently discovered that a subset of DCs in the gut can resist lethal doses of radiation, raising the possibility that LCs may not be unique in being radio-resistant; other tissues may harbor radio- resistant populations that contribute to GVHD. Thus, in aim 1, we will examine the turnover of DCs in the gut, a tissue that is particularly affected by GVHD. Gut DCs constantly transport commensal bacteria and pathogens from the luminal intestine to local lymphoid tissues, playing a critical role in innate and adaptive immunity. To face their continuous migration, gut DCs must be replaced with new cells, but the nature of the committed precursor that maintains the gut DC pool remains elusive. Using novel strategies, we have recently characterized the circulating LC precursor as being a specific subset of circulating monocytes. We also established the sequence of events that leads a monocyte to become a LC and discovered that signaling through the receptor for CSF-1 is required for this process (Nature Immunology in press). Therefore in aim 2, we propose to use similar approaches to explore DC homeostasis in the gut in the steady state and identify the circulating precursor that gives rise to intestinal DCs. Finally, our finding that induction of DC chimerism is critical to prevent GVHD leads us, in aim 3, to determine the nature of the circulating precursor that repopulates DCs in a clinically relevant model for allo-BMT.
描述(由申请人提供):树突状细胞(DC)是在所有淋巴和非淋巴组织中发现的高度特化的抗原呈递细胞。在传统观点中,DC是终末分化的细胞,不断被循环前体库取代。与此观点相反,我们最近证明,在小鼠中,表皮DC也称为朗格汉斯细胞(LC),在静止皮肤中的整个生命周期中由局部抗辐射增殖前体维持,并且仅在损伤期间被循环前体取代。我们还发现,宿主抗辐射LC可以在异基因骨髓移植(allo-BMT)后在受体小鼠中持续存在。移植物抗宿主病(GVHD)是异基因骨髓移植后死亡和发病的主要原因。更重要的是,我们发现异基因骨髓移植后宿主LCs的持续存在与严重的皮肤GVHD相关,而供体LCs替代宿主LCs可改善皮肤GVHD结果。因此,探索DC在GVHD组织靶点中的稳态可能有助于开发治疗这种毁灭性疾病的新策略。除了LC之外,我们最近发现肠道中的DC亚群可以抵抗致死剂量的辐射,这提高了LC可能不是唯一具有辐射抗性的可能性;其他组织可能具有导致GVHD的辐射抗性群体。因此,在目标1中,我们将检查肠道中DC的周转,肠道是特别受GVHD影响的组织。肠道DCs能将肠道内的细菌和病原体不断地运送到局部淋巴组织,在先天性免疫和适应性免疫中发挥重要作用。为了应对它们的持续迁移,肠道DC必须被新细胞取代,但维持肠道DC库的定型前体的性质仍然难以捉摸。使用新的策略,我们最近的特点是循环LC前体作为循环单核细胞的一个特定的子集。我们还建立了导致单核细胞成为LC的事件序列,并发现通过CSF-1受体的信号传导是该过程所需的(Nature Immunology出版)。因此,在目标2中,我们提出使用类似的方法来探索稳态下肠道中的DC稳态,并鉴定产生肠道DC的循环前体。最后,我们发现DC嵌合体的诱导对于预防GVHD是至关重要的,这使我们在目标3中确定在临床相关的allo-BMT模型中重新填充DC的循环前体的性质。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MIRIAM MERAD其他文献

MIRIAM MERAD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MIRIAM MERAD', 18)}}的其他基金

Type 2 immunity: a primitive response to epithelial injury that shapes bone marrow and lung myeloid crosstalk
2型免疫:对上皮损伤的原始反应,形成骨髓和肺髓细胞串扰
  • 批准号:
    10577950
  • 财政年份:
    2023
  • 资助金额:
    $ 42.38万
  • 项目类别:
Core D - Immune Monitoring Core
核心 D - 免疫监测核心
  • 批准号:
    10153660
  • 财政年份:
    2020
  • 资助金额:
    $ 42.38万
  • 项目类别:
Harnessing Csf-2 compartmentalized role on tissue resident phagocytes to uncouple anti-tumoral from pathological immunity induced by checkpoint inhibitors
利用 Csf-2 对组织驻留吞噬细胞的区室化作用,将抗肿瘤作用与检查点抑制剂诱导的病理免疫作用分开
  • 批准号:
    9228983
  • 财政年份:
    2015
  • 资助金额:
    $ 42.38万
  • 项目类别:
Peripheral IL-6 from leukocytes controls susceptibility to social defeat stress
来自白细胞的外周 IL-6 控制对社交失败压力的易感性
  • 批准号:
    8750561
  • 财政年份:
    2014
  • 资助金额:
    $ 42.38万
  • 项目类别:
Peripheral IL-6 from leukocytes controls susceptibility to social defeat stress
来自白细胞的外周 IL-6 控制对社交失败压力的易感性
  • 批准号:
    9095901
  • 财政年份:
    2014
  • 资助金额:
    $ 42.38万
  • 项目类别:
Peripheral IL-6 from leukocytes controls susceptibility to social defeat stress
来自白细胞的外周 IL-6 控制对社交失败压力的易感性
  • 批准号:
    9275540
  • 财政年份:
    2014
  • 资助金额:
    $ 42.38万
  • 项目类别:
Peripheral IL-6 from leukocytes controls susceptibility to social defeat stress
来自白细胞的外周 IL-6 控制对社交失败压力的易感性
  • 批准号:
    8896878
  • 财政年份:
    2014
  • 资助金额:
    $ 42.38万
  • 项目类别:
Peripheral IL-6 from leukocytes controls susceptibility to social defeat stress
来自白细胞的外周 IL-6 控制对社交失败压力的易感性
  • 批准号:
    9487761
  • 财政年份:
    2014
  • 资助金额:
    $ 42.38万
  • 项目类别:
Characterizing a New Human Dendritic Cell Lineage and Its Role in LCH
人类新树突状细胞谱系的表征及其在 LCH 中的作用
  • 批准号:
    8597535
  • 财政年份:
    2011
  • 资助金额:
    $ 42.38万
  • 项目类别:
Role of Mucosal DC Subsets in the Control of Influenza A Virus Immunity
粘膜 DC 亚群在控制甲型流感病毒免疫中的作用
  • 批准号:
    8294597
  • 财政年份:
    2011
  • 资助金额:
    $ 42.38万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 42.38万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 42.38万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 42.38万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 42.38万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 42.38万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 42.38万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 42.38万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 42.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了